Protocol Ledger

NCT07486817 · Phase II · RECRUITING

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

Interventional Phase II clinical trial protocol NCT07486817 sponsored by Boehringer Ingelheim in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-04 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07486817
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07486817
Protocol FieldVerified Registry Value
NCT IdentifierNCT07486817
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2026-06-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07486817
Hospital Research SiteLocationSite Profile
Royal North Shore HospitalSt Leonards, AustraliaOpen Hospital Dossier ->
Fiona Stanley HospitalMurdoch, AustraliaOpen Hospital Dossier ->
Guangdong Provincial People's HospitalGuangzhou, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI